NCT01950780View on ClinicalTrials.gov

Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Alopecia Areata
Interventions
DRUG

Ruxolitinib

A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.

Trial Locations (1)

10032

Columbia University Medical Center, Department of Dermatology, New York

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

Locks of Love

OTHER

lead

Columbia University

OTHER

NCT01950780 - Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata | Biotech Hunter | Biotech Hunter